Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Lung involvement during the prediagnostic phase of idiopathic pleuroparenchymal fibroelastosis

Takuto Miyamura, Yoshiaki Kinoshita, Hisako Kushima, Hiroshi Mukae, Hiroshi Ishii
ERJ Open Research 2022 8: 00548-2021; DOI: 10.1183/23120541.00548-2021
Takuto Miyamura
1Dept of Respiratory Medicine, Fukuoka University Chikushi Hospital, Fukuoka, Japan
3These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiaki Kinoshita
1Dept of Respiratory Medicine, Fukuoka University Chikushi Hospital, Fukuoka, Japan
3These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisako Kushima
1Dept of Respiratory Medicine, Fukuoka University Chikushi Hospital, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Mukae
2Dept of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Ishii
1Dept of Respiratory Medicine, Fukuoka University Chikushi Hospital, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hiroshi Ishii
  • For correspondence: hishii@fukuoka-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Patients with PPFE sometimes have lung involvement at the lung apex long before the diagnosis. The prediagnostic phase with apical fibrosis is much longer than the postdiagnostic phase in patients with PPFE. https://bit.ly/32X1iXi

To the Editor:

Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a rare interstitial pneumonia that predominantly affects the upper lung fields [1, 2]. A pulmonary apical cap (PAC) is an imaging finding resembling that for PPFE that does not show symptoms or progression [3, 4]. Some patients with PPFE have recognised lung involvement at the lung apex long before the diagnosis is actually made, findings that are indistinguishable from PAC based on temporal imaging data [5]. Clinically, it takes months to years from the first recognition of lung involvement to the diagnosis of PPFE [6, 7]. However, no study has yet focused on the progression of lung involvement or the clinical course before the diagnosis of IPPFE. The present study evaluated the prediagnostic clinical course in patients with IPPFE.

The Fukuoka University Chikushi Hospital Institutional Review Board approved the study protocol and waived the requirement for informed consent (approval number: C20-09-002). We examined consecutive patients who were diagnosed with IPPFE at Fukuoka University Chikushi Hospital from January 2010 to December 2020. We extracted patients who had had chest images collected for follow-up of lung involvement or other diseases or who had undergone medical check-ups over a period of more than five years before the diagnosis of IPPFE. We reevaluated the patients to confirm the diagnosis according to the diagnostic criteria of IPPFE [7]. We extracted the first day that patients complained about the symptoms, the date of the diagnosis, and the last day of observation (death or last survival follow-up) from the medical records. The date of the diagnosis was set as the date at which PPFE was first described as the diagnosis in the medical record. We defined apical fibrosis as linear or curved density at the lung apex on chest radiography or subpleural wedge-shaped consolidation at the lung apex on chest computed tomography [8, 9]. Two experienced pulmonary physicians (T.M. and Y.K.) evaluated all chest radiography and computed tomography images collected before the diagnosis. The date of the first recognition of apical fibrosis was defined as the date on which either investigator first recognised apical fibrosis, and the deterioration date was defined as the date on which both investigators decided that apical fibrosis had worsened beyond the date of first recognition. Continuous data are shown as the group median (interquartile range), and categorical data are shown as the number (percentage).

A total of 49 patients were diagnosed with IPPFE during the period, and 20 patients were eligible for this study. The clinical characteristics of the enrolled patients were as follows: 15 men and 5 women; 74 (71–78) years old; body mass index of 18.9 (17.1–20.0) kg·m−2; forced vital capacity of 2115 (1580–2430) mL (68.2% (50.2%–84.7%)); and residual volume/total lung capacity of 0.48 (0.41–0.50) (119% (107%–131%)). Ten of the 20 patients (50%) were complicated with interstitial pneumonia other than PPFE in the lower lobes. The period from the oldest radiographic examination to the diagnosis was 7.82 (5.80–12.9) years. The mean frequency of radiological examinations before the diagnosis per patient was 1.59 times per year: 0.90 (0.53–1.41) times per year for chest radiography and 0.59 (0.27–0.74) times per year for chest CT. The period from the first recognition of apical fibrosis to the last observation was 6.71 (6.14–9.98) years, consisting of 5.94 (5.40–7.35) years from the first recognition of apical fibrosis to the diagnosis and 0.93 (0.57–1.42) years from the diagnosis to the last observation. The percentage of the time from the diagnosis to the last observation against the time from the first recognition of apical fibrosis to the last observation was calculated to be 13.8% (0.93/6.71 years). The period from the first recognition of apical fibrosis to the deterioration was 5.38 (1.86–6.39) years. Eleven of the 20 patients (55%) had apical fibrosis that had not progressed for more than 5 years before the diagnosis. The period from the symptoms to the diagnosis was 1.66 (0.86–3.61) years. The results for each patient are shown in figure 1.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

The results of the radiological assessment and clinical course in 20 patients with idiopathic pleuroparenchymal fibroelastosis. The green bar indicates the period for which apical fibrosis was detected before the diagnosis of idiopathic pleuroparenchymal fibroelastosis. The mean period (interquartile range) from the first recognition of apical fibrosis to the deterioration (from the left end of the green bar to the red triangle) was 5.38 (1.86–6.39) years.

The early stage of PPFE is sometimes indistinguishable from PAC based on temporal imaging data [7]. Differentiating the two entities requires a retrospective review or prospective follow-up of the imaging data [3, 5, 7]. In this study, the period from the first recognition of apical fibrosis to the deterioration was 5.38 (1.86–6.39) years, suggesting the difficulty in differentiating PPFE from PAC by a short-term observation. PAC is a relatively common imaging finding. Renner et al. [8] identified a unilateral PAC in 11.2% and a bilateral PAC in 10.9% by routine chest radiography. Therefore, from a cost-effectiveness perspective, it might be wasteful to follow all patients with lung involvement at the lung apex. However, we should carefully examine the lung involvement of patients with apical fibrosis over a relatively long period, as the prediagnostic phase of PPFE is indistinguishable from PAC by short-term observation. PPFE should be at least considered when patients with apical fibrosis complain of respiratory symptoms during the course of the disease.

Marinescu et al. [10] recently described a patient with PAC that evolved into PPFE after lung surgery and speculated that the presence of PAC predisposes patients to PPFE development when faced with ongoing inflammatory injury. Although the insults were unidentified in patients with IPPFE and whether this apical fibrosis should be recognised as PAC or an early phase of PPFE was an intrinsic problem, we showed that half of the patients with IPPFE had apical fibrosis that did not progress long before the diagnosis. The idea that PAC is a risk factor for PPFE may apply not only to post-operative PPFE but also to IPPFE. It may be necessary to recognise PAC and PPFE as part of the same spectrum rather than as separate concepts, as their pathology shares the common finding of subpleural fibroelastosis, aside from the extent of the lesion [3, 9]. Of note, Egashira et al. [11] showed that the risk factors for progression of apical fibrosis in patients with apical fibrosis detected on daily computed tomography was a horizontal extent of apical fibrosis (proportion of lesion to the whole circumference at the most affected section) exceeding 25%. Therefore, patients with extensive apical fibrosis might need to be radiologically followed for short-term observation. The prognosis after the diagnosis of IPPFE is poor, with 5-year survival rates of 23.3%-58.9% [12–16]. The percentage of the time from the diagnosis to the last observation in the time from the first recognition of fibrosis to the last observation was 13.8%. Therefore, if the clinical course of PPFE is perceived as the entire period with apical fibrosis, the duration of undiagnosed IPPFE in the presence of apical fibrosis may be much longer than the clinical course after the diagnosis.

In this study, 10 of the 20 patients were complicated with interstitial pneumonia other than PPFE in the lower lobes. The lower lobe lesions in these patients were radiologically classified as usual interstitial pneumonia (UIP) (n=4), probable UIP (n=3) or unclassifiable interstitial pneumonia (n=3), according to the official American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society clinical practice guidelines of 2018 [17].

We believe that different pathologic processes are at work in the upper and lower lobes, as the pathology differs between PPFE and UIP. We previously suggested that UIP lesions in the lower lobes and PPFE lesions in the upper lobes might both be formed by abnormal healing processes caused by stimuli such as acute lung injury and inflammation, but the eventual pattern of abnormal healing may differ in the upper and lower lobes. In other words, interstitial inflammation and fibrosis as the initial stage might progress to honeycomb lung as end-stage fibrosis in the lower lobes of PPFE patients but be replaced by subpleural fibroelastosis in the upper lobes of PPFE patients [18]. Several limitations associated with the present study warrant mention. First, the timing of the diagnosis may vary, depending on whether or not the clinician is familiar with the diagnosis of PPFE. Second, there were 11 cases (55%) in which apical fibrosis was already present at the initial radiological examination, suggesting that the period from the appearance of apical fibrosis to the diagnosis is longer in these cases. Given the absence of a control group of patients with PAC, it is impossible to suggest follow-up for all patients with PAC. In addition to the small sample size of the study, there were some cases in which the prognosis was not yet determined. In such cases, the observation period after diagnosis will be longer.

Patients with IPPFE sometimes have lung involvement at the lung apex long before the diagnosis. The prediagnostic phase with apical fibrosis was much longer than the postdiagnostic phase in patients with IPPFE. The prediagnostic phase of PPFE is indistinguishable from PAC on short-term observation.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Conflict of interest: T. Miyamura has nothing to disclose.

  • Conflict of interest: Y. Kinoshita has nothing to disclose.

  • Conflict of interest: H. Kushima has nothing to disclose.

  • Conflict of interest: H. Mukae has nothing to disclose.

  • Conflict of interest: H. Ishii has nothing to disclose.

  • Support statement: This study was supported by Japan Society for the Promotion of Science grant JP21K16153. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received September 9, 2021.
  • Accepted December 28, 2021.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Frankel SK,
    2. Cool CD,
    3. Lynch DA, et al.
    Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity. Chest 2004; 126: 2007–2013. doi:10.1378/chest.126.6.2007
    OpenUrlCrossRefPubMed
  2. ↵
    1. Travis WD,
    2. Costabel U,
    3. Hansell DM, et al.
    An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748. doi:10.1164/rccm.201308-1483ST
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kinoshita Y,
    2. Ishii H,
    3. Nabeshima K, et al.
    The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis. Histol Histopathol 2021; 36: 291–303.
    OpenUrl
  4. ↵
    1. Lagstein A
    . Pulmonary apical cap-what's old is new again. Arch Pathol Lab Med 2015; 139: 1258–1262. doi:10.5858/arpa.2015-0224-RA
    OpenUrl
  5. ↵
    1. Watanabe K,
    2. Nagata N,
    3. Kitasato Y, et al.
    Rapid decrease in forced vital capacity in patients with idiopathic pulmonary upper lobe fibrosis. Respir Investig 2012; 50: 88–97. doi:10.1016/j.resinv.2012.06.003
    OpenUrlCrossRefPubMed
  6. ↵
    1. Ricoy J,
    2. Suárez-Antelo J,
    3. Antúnez J, et al.
    Pleuroparenchymal fibroelastosis: clinical, radiological and histopathological features. Respir Med 2021; 4: 106437. doi:10.1016/j.rmed.2021.106437
  7. ↵
    1. Watanabe K,
    2. Ishii H,
    3. Kiyomi F, et al.
    Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: a proposal. Respir Investig 2019; 57: 312–320. doi:10.1016/j.resinv.2019.02.007
    OpenUrl
  8. ↵
    1. Renner RR,
    2. Markarian B,
    3. Pernice NJ, et al.
    The apical cap. Radiology 1974; 110: 569–573. doi:10.1148/110.3.569
    OpenUrlCrossRefPubMed
  9. ↵
    1. Yousem SA
    . Pulmonary apical cap: a distinctive but poorly recognized lesion in pulmonary surgical pathology. Am J Surg Pathol 2001; 25: 679–683. doi:10.1097/00000478-200105000-00018
    OpenUrlCrossRefPubMed
  10. ↵
    1. Marinescu DC,
    2. English J,
    3. Sedlic T, et al.
    Pulmonary apical cap as a potential risk factor for pleuroparenchymal fibroelastosis. Chest 2021; 159: e365–e370. doi:10.1016/j.chest.2021.01.011
    OpenUrl
  11. ↵
    1. Egashira R,
    2. Yamaguchi K,
    3. Kondo T, et al.
    Pleuroparenchymal fibroelastosis (PPFE)-like finding on CT in daily practice -prevalence and serial changes. Eur J Radiol Open 2020; 7: 100296. doi:10.1016/j.ejro.2020.100296
    OpenUrl
  12. ↵
    1. Enomoto Y,
    2. Nakamura Y,
    3. Satake Y, et al.
    Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: a retrospective multicenter study. Respir Med 2017; 133: 1–5. doi:10.1016/j.rmed.2017.11.003
    OpenUrl
    1. Fujisawa T,
    2. Mori K,
    3. Mikamo M, et al.
    Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. Eur Respir J 2019; 53: 1802243. doi:10.1183/13993003.02243-2018
    OpenUrlAbstract/FREE Full Text
    1. Ishii H,
    2. Watanabe K,
    3. Kushima H, et al.
    Pleuroparenchymal fibroelastosis diagnosed by multidisciplinary discussions in Japan. Respir Med 2018; 141: 190–197. doi:10.1016/j.rmed.2018.06.022
    OpenUrl
    1. Nakamura Y,
    2. Mori K,
    3. Enomoto Y, et al.
    Prognostic and clinical value of cluster analysis in idiopathic pleuroparenchymal fibroelastosis phenotypes. J Clin Med 2021; 10: 1498. doi:10.3390/jcm10071498
    OpenUrl
  13. ↵
    1. Suzuki Y,
    2. Fujisawa T,
    3. Sumikawa H, et al.
    Disease course and prognosis of pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis. Respir Med 2020; 171: 106078. doi:10.1016/j.rmed.2020.106078
    OpenUrl
  14. ↵
    1. Raghu G,
    2. Remy-Jardin M,
    3. Myers JL, et al.
    Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198: e44–e68. doi:10.1164/rccm.201807-1255ST
    OpenUrlCrossRefPubMed
  15. ↵
    1. Hirota T,
    2. Yoshida Y,
    3. Kitasato Y, et al.
    Histological evolution of pleuroparenchymal fibroelastosis. Histopathology 2015; 66: 545–554. doi:10.1111/his.12554
    OpenUrlPubMed
PreviousNext
Back to top
Vol 8 Issue 2 Table of Contents
ERJ Open Research: 8 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lung involvement during the prediagnostic phase of idiopathic pleuroparenchymal fibroelastosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Lung involvement during the prediagnostic phase of idiopathic pleuroparenchymal fibroelastosis
Takuto Miyamura, Yoshiaki Kinoshita, Hisako Kushima, Hiroshi Mukae, Hiroshi Ishii
ERJ Open Research Apr 2022, 8 (2) 00548-2021; DOI: 10.1183/23120541.00548-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Lung involvement during the prediagnostic phase of idiopathic pleuroparenchymal fibroelastosis
Takuto Miyamura, Yoshiaki Kinoshita, Hisako Kushima, Hiroshi Mukae, Hiroshi Ishii
ERJ Open Research Apr 2022, 8 (2) 00548-2021; DOI: 10.1183/23120541.00548-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • A 3D-engineered silicone stent
  • Obesity does not modify effect of CPAP on insulin resistance
  • Asthma prevalence and medication dispensation
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society